Assignment of the Human p27Kip1 Gene to 12p13 and Its Analysis in Leukemias

Cancer Research

Volumn 55, Issue 6, 1995, Pages 1206-1210

  Pietenpol, Jennifer A ^a   Papadopoulos, Nickolas ^a   Liu, Bo ^a   Kinzler, Kenneth W ^a   Vogelstein, Bert ^a   Roberts, James M ^b   Friedman, Cynthia ^c   Trask, Barbara J ^c   Bohlander, Stefan K ^d   Sato, Yuko ^d   Rowley, Janet D ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b FRED HUTCHINSON CANCER RESEARCH CENTER   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYCLIN DEPENDENT KINASE; DNA; ENZYME INHIBITOR; GENE PRODUCT; PROTEIN P21; CIP1 PROTEIN; CYCLINE; PROTEIN KINASE;

AMINO ACID SEQUENCE; ARTICLE; CELL CYCLE; CHROMOSOME 12P; CHROMOSOME DELETION; DNA SEQUENCE; EXON; FLUORESCENCE; GENE; HUMAN; HUMAN TISSUE; HYBRID CELL; IN SITU HYBRIDIZATION; LEUKEMIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; CHROMOSOME 12; CHROMOSOME MAP; CHROMOSOME TRANSLOCATION; GENETICS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

BASE SEQUENCE; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 12; CYCLINS; GENES, TUMOR SUPPRESSOR; HUMAN; LEUKEMIA; MOLECULAR SEQUENCE DATA; PROTEIN KINASES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TRANSLOCATION (GENETICS);

EID: 0028986931     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Sherr, C. J. Mammalian Gl cyclins. Cell, 73: 1059–1065, 1993.
2. Serrano, M., Hannon, G. L., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclinD/CDK4. Nature (Lond.), 366: 704–707, 1993.
3. Hannon, G. J., and Beach, D. pl5INK4B is a potential effector of TGF-0-induced cell cycle arrest. Nature (Lond.), 371: 257–261, 1994.
4. Harper, J. W., Adami, G. R., Keyomarsi, K., and Elledge, S. J. The p21 Cdk-interacting protein Cipl is a potent inhibitor of Gl cyclin-dependent kinases. Ceil, 75: 805–816, 1993.
5. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817–825, 1993.
6. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, H., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701–704, 1993.
7. Gu, Y., Turck, C. W., and Morgan, D. O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature (Lond.), 366: 707–710, 1993.
8. Noda, A., Ning, Y., Venable, S. F., Periera-Smith, O. M., and Smith, J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res., 211: 90–98, 1994.
9. Polyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M., and Koff, A. p27kip1, a cyclin-Cdk inhibitor, links transforming growth factor-B and contact inhibition to cell cycle arrest. Genes Dev., 8: 9–22, 1994.
10. Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., and Massaque, J. Cloning of p27Kipl, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59–66, 1994.
11. Toyoshima, H., and Hunter, T. p27, a novel inhibitor of Gl cyclin-cdk protein kinase activity, is related to p21. Cell, 78: 67–74, 1994.
12. Firpo, E. J., Koff, A., Solomon, M. J., and Roberts, J. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol. Cell. Biol., 14: 4889–4901, 1994.
13. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavitigian, S. V., Stochert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436–440, 1994.
14. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753–756, 1994.
15. Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., Beach, D. H., and Harris, C. C. Mutations and altered expression of pl6INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045–11049, 1994.
16. Mori, T., Miura, K., Aoki, T., Nishihira, T., Mori, S., and Nakamura, Y. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54: 3396–3397, 1994.
17. Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., and Kern, S. E. Frequent somatic mutations and homozygous deletions in the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet., 8: 27–32, 1994.
18. He, J., Allen, J. R., Collins, V. P., Allalunis-Turner, M. J., Godbout, R., Day, R. S., III, and James, C. D. CDK4 amplification is an alternative mechanism to pl6 gene homozygous deletion in glioma cell lines. Cancer Res., 54: 5804–5807, 1994.
19. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., and Dracopoli, N. C. Germline p16 mutations in familial melanoma. Nat. Genet., 8: 15–21, 1994.
20. Kamb, A., Shattuuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., McClure, M., Aitken, J. F., Anderson, D. E., Bergman, W., Frants, R., Goldgar, D. E., Green, A., MacLennan, R., Martin, N. G., Meyer, L. J., Youl, P., Zone, J. J., Skolnick, M. H., and Cannon-Albright, L. A. Analysis of the pl6 gene {CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet., 8: 22–26, 1994.
21. Jen, J., Harper, J. W., Bigner, S. H., Bigner, D. D., Papadopoulos, N., Markowitz, S., Willson, J. K. V., Kinzler, K. W., and Vogelstein, B. Deletion of p16 and p15 genes in brain tumors. Cancer Res., 54: 6353–6358, 1994.
22. El-Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Canman, C. E., Jackman, J., Pietenpol, J. A., Burrell, M., Hill, D. E., Wang, Y., Wiman, K. G., Mercer, W. E., Kastan, M. B., Kohn, K. W., Elledge, S. J., Kinzler, K. W., and Vogelstein, B. WAF/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54: 1169–1174, 1994.
23. Shiohara, M., El-Deiry, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D.-L., Vogelstein, B., and Koeffler, H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781–3784, 1994.
24. Moses, H. L., Tucker, R. F., Leof, E. B., Coffey, R. J., Jr., Halper, J., and Shipley, G. D. Type 0 transforming growth factor is a growth stimulator and a growth inhibitor. Cancer Cells (Cold Spring Harbor), 3: 65–71, 1985.
25. Papadopoulos, N., Nicolaides, N. C., Wei, Y.-F., Rube, S. M., Carter, K. C., Rosen, C. A., Haseltine, W. A., Fleischmann, R. D., Fraser, C. M., Adams, M. D., Venter, J. C., Hamilton, S. R., Petersen, G. M., Watson, P., Lynch, H. T., Peltomaki, P., Mecklin, J.-P., de la Chapelle, A., Kinzler, K. W., and Vogelstein, B. Mutation of a mutL homolog in hereditary colon cancer. Science (Washington DC), 263: 1625–1629, 1994.
26. Goelz, S. E., Hamilton, S. R., and Vogelstein, B. Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem. Biophys. Res. Com-mun., 130: 118–126, 1985.
27. Trask, B. J. DNA sequence localization in metaphase and interphase cells by fluorescence in situ hybridization. Methods Cell Biol., 35: 3–35, 1991.
28. Cherif, D., Julier, C., Delattre, O., Derre, J., Lathrop, G. M., and Berger, R. Simultaneous localization of cosmids and chromosome R-banding by fluorescence microscopy: application to regional mapping of human chromosome 11. Proc. Natl. Acad. Sci. USA, 87: 6639–6643, 1991.
29. Bohlander, S. K., Espinosa, R., Feraald, A. A., Rowley, J. D., Le Beau, M. M., and Diaz, M. O. Sequence-independent amplification and labeling of yeast artificial chromosomes for fluorescence in situ hybridization. Cytogenet. Cell Genet., 65: 108–110, 1994.
30. Rowley, J. D., Diaz, M. O., Espinosa, R., Patel, Y. D., van Melle, E., Ziemin, S., Taillon-Miller, P., Lichter, P., Evans, G. A., Kersey, J. H., Ward, D. C., Domer, P. H., and Le Beau, M. M. Mapping chromosome band llq23 in human acute leukemia with biotinylated probes: identification of llq23 translocation breakpoints with a yeast artificial chromosome. Proc. Natl. Acad. Sci. USA, 87: 9358–9362, 1990.
31. Kobayashi, H., Montgomery, K. T., Bohlander, S. K., Adra, C. N., Lim, B. L., Kucherlapati, R. S., Donis-Keller, H., Holt, M. S., Le Beau, M. M., and Rowley, J. D. Fluorescence in situ hybridization mapping of translocations and deletion involving the short arm of human chromosome 12 in malignant hematologic diseases. Blood, 84: 3473, 1994.
32. Ponce-Castaneda, M. V., Lee, M.-H., Latres, E., Polyak, K., Lacombe, L., Montgomery, K., Mathew, S., Krauter, K., Schinfeld, J., Massague, J., and Cordon-Cardo, C. p27Kipl: chromosomal mapping to 12pl2 and absence of mutations in human tumors. Cancer Res., 55: 1211–1214, 1995.
33. Bullrich, F., MacLachlan, T. K., Sang, N., Druck, T., Veronese, M. L., Allen, S. L., Chlorazzi, N., Koff, A., Heubner, K., Croce, C. M., and Giordano, A. Chromosomal mapping of members of the cdc2 family of protein kinases cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, plikip1, to regions involved in cancer. Cancer Res., 55: 1199–1205, 1995.
34. Knudson, A. G. Antioncogenes and human cancer. Proc. Natl. Acad. Sci. USA, 90: 10914–10921, 1993.
35. Sato, Y., Suto, Y., Pietenpol, J. A., Golub, T. R., Gilliland, D. G., Roberts, J. M., Trask, B. J., Le Beau, M. M., Vogelstein, B., Rowley, J. D., and Bohlander, S. K. TEL and the gene for p27Kipl are frequently deleted in patients with 12pl3 rearrangements and hematopoietic malignancies. Blood, 84: 292a, 1994.
36. Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M.-H., Massaque, J., Crabtree, G., and Roberts, J. Rapamycin prevents interleukin-2-mediated elimination of the cyclin-dependent-kinase inhibitor, p27Kipl. Nature (Lond.), in press, 1995.